

Analisa DiFeo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1590321/publications.pdf>

Version: 2024-02-01

74
papers

3,763
citations

117571

34
h-index

133188

59
g-index

79
all docs

79
docs citations

79
times ranked

5762
citing authors

#	ARTICLE	IF	CITATIONS
1	microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelialâ€mesenchymal transition. <i>Nature Communications</i> , 2014, 5, 2977.	5.8	226
2	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. <i>Cancer Research</i> , 2005, 65, 1213-1222.	0.4	202
3	Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. <i>Human Molecular Genetics</i> , 2007, 16, 1113-1123.	1.4	202
4	Mutations in Capillary Morphogenesis Gene-2 Result in the Allelic Disorders Juvenile Hyaline Fibromatosis and Infantile Systemic Hyalinosis. <i>American Journal of Human Genetics</i> , 2003, 73, 957-966.	2.6	174
5	Critical role of Wnt/ β 2-catenin signaling in driving epithelial ovarian cancer platinum resistance. <i>Oncotarget</i> , 2015, 6, 23720-23734.	0.8	158
6	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. <i>Journal of Clinical Investigation</i> , 2017, 127, 2081-2090.	3.9	155
7	Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. <i>Cancer Research</i> , 2005, 65, 5761-5768.	0.4	151
8	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1047-1052.	3.6	142
9	Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. <i>Nature Medicine</i> , 2018, 24, 176-185.	15.2	126
10	The role of KLF6 and its splice variants in cancer therapy. <i>Drug Resistance Updates</i> , 2009, 12, 1-7.	6.5	112
11	Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. <i>Clinical Cancer Research</i> , 2006, 12, 3730-3739.	3.2	103
12	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , 2008, 118, 2711-2721.	3.9	97
13	Ribosomeâ€inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylaseâ€1 selectively in premalignant and malignant prostate cancer cells. <i>International Journal of Cancer</i> , 2009, 125, 774-782.	2.3	87
14	Myosin IIA Associates with NK Cell Lytic Granules to Enable Their Interaction with F-Actin and Function at the Immunological Synapse. <i>Journal of Immunology</i> , 2009, 182, 6969-6984.	0.4	85
15	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. <i>Journal of Clinical Investigation</i> , 2012, 122, 2637-2651.	3.9	79
16	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	1.8	75
17	Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. <i>Oncogene</i> , 2018, 37, 403-414.	2.6	74
18	E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. <i>Oncogene</i> , 2006, 25, 6026-6031.	2.6	73

#	ARTICLE	IF	CITATIONS
19	Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. <i>International Journal of Cancer</i> , 2007, 121, 1390-1395.	2.3	73
20	Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating CollagenAI Expression. <i>Digestive Diseases and Sciences</i> , 2011, 56, 406-416.	1.1	70
21	KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. <i>Science Translational Medicine</i> , 2013, 5, 169ra12.	5.8	70
22	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. <i>Journal of Experimental Medicine</i> , 2017, 214, 2715-2732.	4.2	67
23	Altered glutamine metabolism in platinum resistant ovarian cancer. <i>Oncotarget</i> , 0, 7, 41637-41649.	0.8	65
24	A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response. <i>Cancer Research</i> , 2008, 68, 965-970.	0.4	61
25	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 2065-2080.	0.4	60
26	Cisplatin induces stemness in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 30511-30522.	0.8	58
27	Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage IIâ€“III Resectable Disease. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2202-2211.	0.3	51
28	Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. <i>Blood</i> , 2011, 118, 5862-5871.	0.6	50
29	Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. <i>Annals of Oncology</i> , 2016, 27, 625-634.	0.6	50
30	Functional role of the KLF6 tumour suppressor gene in gastric cancer. <i>European Journal of Cancer</i> , 2009, 45, 666-676.	1.3	48
31	Crowdsourcing Awareness: Exploration of the Ovarian Cancer Knowledge Gap through Amazon Mechanical Turk. <i>PLoS ONE</i> , 2014, 9, e85508.	1.1	42
32	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. <i>Molecular Cancer Research</i> , 2019, 17, 1815-1827.	1.5	40
33	Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 4599-4611.	0.4	39
34	KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model. <i>Cancer Research</i> , 2009, 69, 4733-4741.	0.4	38
35	The Highly Recurrent PP2A AÎ±-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. <i>Cancer Research</i> , 2019, 79, 4242-4257.	0.4	37
36	Ligand-dependent Corepressor (LCoR) Recruitment by KrÃ¼ppel-like Factor 6 (KLF6) Regulates Expression of the Cyclin-dependent Kinase Inhibitor CDKN1A Gene. <i>Journal of Biological Chemistry</i> , 2012, 287, 8662-8674.	1.6	36

#	ARTICLE	IF	CITATIONS
37	RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. <i>Oncogene</i> , 2016, 35, 1363-1372.	2.6	36
38	KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2007, 121, 1976-1983.	2.3	34
39	Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. <i>Human Mutation</i> , 2009, 30, 583-589.	1.1	30
40	miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. <i>Biomarkers in Medicine</i> , 2015, 9, 241-257.	0.6	26
41	Nucleo-Cytoplasmic Localization Domains Regulate Krüppel-Like Factor 6 (KLF6) Protein Stability and Tumor Suppressor Function. <i>PLoS ONE</i> , 2010, 5, e12639.	1.1	26
42	Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. <i>Oncogene</i> , 2020, 39, 703-717.	2.6	24
43	miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. <i>Nature Communications</i> , 2020, 11, 3231.	5.8	24
44	The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 2044-2055.	0.4	21
45	A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. <i>Annals of Oncology</i> , 2016, 27, 1511-1519.	0.6	20
46	InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer. <i>Oncogene</i> , 2017, 36, 2472-2482.	2.6	20
47	Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. <i>Lung Cancer</i> , 2009, 66, 292-297.	0.9	19
48	Multiple Breast Cancer Cell-Lines Derived from a Single Tumor Differ in Their Molecular Characteristics and Tumorigenic Potential. <i>PLoS ONE</i> , 2013, 8, e55145.	1.1	19
49	Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2481-2489.	1.9	18
50	KLF6 is one transcription factor involved in regulating acid ceramidase gene expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1732, 82-87.	2.4	17
51	miR-181a modulates circadian rhythm in immortalized bone marrow and adipose derived stromal cells and promotes differentiation through the regulation of PER3. <i>Scientific Reports</i> , 2019, 9, 307.	1.6	16
52	The Molecular Mechanisms behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9486.	1.8	15
53	Torg-Winchester syndrome: lack of efficacy of pamidronate therapy. <i>Clinical Dysmorphology</i> , 2007, 16, 95-100.	0.1	14
54	Emerging Roles of Kruppel-Like Factor 6 and Kruppel-Like Factor 6 Splice Variant 1 in Ovarian Cancer Progression and Treatment. <i>Mount Sinai Journal of Medicine</i> , 2009, 76, 557-566.	1.9	13

#	ARTICLE	IF	CITATIONS
55	Bladder exstrophy and Epstein type congenital macrothrombocytopenia: Evidence for a common cause?. American Journal of Medical Genetics, Part A, 2006, 140A, 2251-2253.	0.7	11
56	Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clinical Cancer Research, 2018, 24, 4588-4601.	3.2	11
57	Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. Reproductive Sciences, 2019, 26, 609-618.	1.1	10
58	A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports, 2019, 12, 122-134.	2.3	8
59	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. PLoS ONE, 2020, 15, e0240169.	1.1	8
60	Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecologic Oncology, 2018, 151, 525-532.	0.6	7
61	<scp>STING</scp> pathway expression in lowâ€grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. Journal of Pathology: Clinical Research, 2021, 7, 548-555.	1.3	6
62	A new feature of the MYH9-related syndrome: Chronic transaminase elevation. Hepatology, 2013, 57, 1288-1289.	3.6	5
63	Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts. Diagnostics, 2021, 11, 181.	1.3	5
64	Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. Cancer Research, 2022, 82, 721-733.	0.4	4
65	Repurposed Drugs Trials for Ovarian Cancer. Cancer Journal (Sudbury, Mass), 2019, 25, 149-152.	1.0	3
66	The first report of homozygous May-Hegglin anomaly E1841K mutation. European Journal of Haematology, 2011, 86, 357-357.	1.1	2
67	Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. Case Reports in Oncology, 2021, 14, 224-231.	0.3	2
68	Host and Tumor Factor XII Drive Ovarian Cancer Maintenance and Progression. Blood, 2019, 134, 2384-2384.	0.6	2
69	KrÃ¼ppel-like Factors KLF6 and KLF6-SV1 in the Diagnosis and Treatment of Cancer. , 2009, , 223-244.		0
70	Prognostic influence of BRCA 1 somatic mutations in African American versus Caucasian ovarian cancer patients.. Journal of Clinical Oncology, 2017, 35, e17054-e17054.	0.8	0
71	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0
72	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0

#	ARTICLE	IF	CITATIONS
73	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0
74	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0